期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血清M30水平与丙型肝炎引起的并发症相关研究

下载PDF
导出
摘要 目的检测丙型肝炎病毒感染后血清中的M30水平与肝脏继发性病变的关系。方法选择200例未经治疗的丙型肝炎患者和100例健康对照者,检测丙型肝炎患者和健康人群血清M30水平并对丙型肝炎患者肝脏活检标本进行:METAVIR纤维化分级、组织活动指数(Histology Aotivity Index,HAI)炎症评分和脂肪变性分级。结果丙型肝炎患者血清M30水平(298±70.8)U/L显著高于健康对照组(135±33.8)U/L,(P<0.01);在丙型肝炎患者中M30水平和肝纤维化有关,M30水平随着患者肝纤维化程度的加深而升高,F2(348±50.9)U/L,F3(385±3l.2)U/L,F4(368±40.1)U/L显著高于F0(235±26.1)U/L和FI(252±60.3)U/L(P<0.05);M30水平和肝脂肪变性有关,随着脂肪变性评级的上升,丙型肝炎患者血清中M30水平也上升,2级(368±31.2)U/L,3级(387±20.4)U/L显著高于0级(226±46.9)U/L和1级(279±80.4)U/L(P<0.05);丙型肝炎患者M30水平和HAI评分无统计学意义(P>0.05)。结论血清M30水平能提示丙型肝炎患者肝纤维化和脂肪化的程度。
作者 龚艳容 陈娜 张幸国
机构地区 浙江大学医学院附属第一医院
出处 《浙江实用医学》 2013年第3期175-176,共2页 Zhejiang Practical Medicine
关键词 丙型肝炎 肝纤维化 肝脂肪化 M30
分类号 R512.63 [医药卫生—内科学]
  • 相关文献

参考文献7

  • 1丙型肝炎防治指南[J].中华传染病杂志,2004,22(2):131-136. 被引量：225
  • 2Theise N D, Bordenheimer H C, Ferrel L D. 2007 Acute and chronicviral hepatitis. Mac Sweens Pathology of the liver, 2007,8(5) :418.
  • 3Knodell R G, Ishak K G, Black W C. et al, Formulation and appli-cation of a numerical scoring system for assessing histological activityin asymptomatic chronic active hepatitis. Hepatology, 1981,1(5) :431.
  • 4Cheong J Y, Kim Cho S W, et al. Serum markers for necroinflamma-tory activity in patients with chronic viral hepatitis and normal or mild-ly elevated aminotransferase levels. Liver Int,2011,31 (9):1352.
  • 5Papatheodoridis G V,Hadziyannis E, Tsochatzis E, et al. Serumapoptotic caspase activity in chronic hepatitis C and nonalcoholic fattyliver disease. J Clin Gastroenterol, 2010,44(4) : 87.
  • 6董秋艳,韩涛,朱争艳,李岩,肖时湘,刘莹,刘欢,郭震.非酒精性脂肪肝患者血清CK-18 M30水平的测定[J].天津医科大学学报,2011,17(4):486-489. 被引量：3
  • 7Ounossi Z M, Jarrar M, Nugent C,et al. A noveldiagnostic biomarkerpanel for obesity - related nonaloholic, steatohepatitis (NASH). ObesSurg, 2008, 18(11): 1430.

二级参考文献26

  • 1Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol, 2009, 50(1):204.
  • 2Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liv- er disease: a spectrum of clinical and pathological severity [J]. Gas- troenterology, 1999, 116(6):1413.
  • 3Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotrans- ferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease[J]. Am J Gastroenterol, 1999, 94(4): 1018.
  • 4de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears[J]. J Hepatol, 2008,48 (Suppl 1):S 104.
  • 5Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liv- er cell apoptosis as a novel biomarker of disease severity in nonal- coholic fatty liver disease[J]. Hepatology, 2006, 44(1):27.
  • 6Feldstein AE, Canbay A, Guicciardi ME, et al. Diet associated hep atic steatosis sensitizes to fas mediated liver injury in mice [J]. J Hepatol,2003, 39 (6) : 978.
  • 7Begriche K, Igoudjil A, Pessayre D, et al. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it[J]. Mitochondrion, 2006, 6 (1): 1.
  • 8Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury[J]. J Clin Invest, 2004, 114 (2):147.
  • 9Tanaka N, Moriya K, Kiyosawa K, et al. PPARalpha activation is es- sential for HCV core protein-induced hepatic steatosis and hepato- cellular carcinoma in mice[J]. J Clin Invest ,2008,118(2):683.
  • 10Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas-expression are prominent features of human nonalcoholic steatohepatitis[J]. Gastroenterology, 2003, 125 (2):437.

共引文献226

浙江实用医学
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部